[Effect of HMG-CoA reductase inhibitors on the erythrocyte membrane]

Area of Science:

• Biochemistry
• Clinical Medicine
• Pharmacology

Background:

• Primary hypercholesterolemia is a condition characterized by elevated cholesterol levels.
• Statins, like simvastatin, are commonly used to manage hypercholesterolemia by inhibiting cholesterol synthesis.

Purpose of the Study:

• To investigate the effects of simvastatin on erythrocyte membrane properties in patients with primary hypercholesterolemia.
• To explore potential alterations in cholesterol exchange between plasma and erythrocyte membranes during simvastatin therapy.

Main Methods:

• A double-blind, placebo-controlled clinical trial involving 10 patients with primary hypercholesterolemia.
• Serum lipid profiles (total cholesterol, HDL-cholesterol, triglycerides, apolipoproteins A1 and B) were measured monthly.
• Erythrocyte membrane parameters including cholesterol and phospholipid concentration, Na+/K+ ATPase activity, and fluidity were assessed at monthly intervals.

Main Results:

• Simvastatin treatment led to an initial increase in erythrocyte membrane cholesterol concentration and cholesterol/phospholipid ratio, followed by a significant decrease after 4 months.
• Erythrocyte membrane fluidity initially decreased, then increased after 4 months of simvastatin treatment.
• Na+/K+ ATPase activity in erythrocyte membranes increased significantly only after 4 months of simvastatin therapy.

Conclusions:

• Simvastatin treatment significantly modifies erythrocyte membrane composition and function in patients with primary hypercholesterolemia.
• These findings suggest that simvastatin may influence the exchange of cholesterol between plasma and cell membranes, beyond its known effect on hepatic cholesterol synthesis.